Changes after behavior therapy among responsive and nonresponsive patients with obsessive-compulsive disorder

Psychiatry Research - Neuroimaging

Volumn 172, Issue 3, 2009, Pages 242-250

  Yamanishi, Tomoaki ^a   Nakaaki, Shutaro ^a   Omori, Ichiro M ^a   Hashimoto, Nobuhiko ^a   Shinagawa, Yoshihiro ^a   Hongo, Jin ^a   Horikoshi, Masaru ^b   Tohyama, Junko ^c   Akechi, Tatsuo ^a   Soma, Tsutomu ^d,e   Iidaka, Tetsuya ^f   Furukawa, Toshi A ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c Toyota Tsusho Corporation   (Japan)

^d FUJIFILM RI Pharma Co Ltd   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Medial prefrontal cortex; Middle frontal cortex; Orbitofrontal cortex; Single photon emission computed tomography; Statistical parametric mapping

Indexed keywords

CLOMIPRAMINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TECHNETIUM 99M;

ADULT; ARTICLE; BEHAVIOR THERAPY; BRAIN BLOOD FLOW; BRAIN MAPPING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HUMAN; JAPAN; MALE; NEUROIMAGING; OBSESSIVE COMPULSIVE DISORDER; ORBITAL CORTEX; PARAMETRIC TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; BEHAVIOR THERAPY; BRAIN; CYSTEINE; FEMALE; FRONTAL LOBE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; OBSESSIVE-COMPULSIVE DISORDER; ORGANOTECHNETIUM COMPOUNDS; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 67349098145     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2008.07.004     Document Type: Article

References (48)

1. Abramowitz J.S., Foa E.B., and Franklin M.E. Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions. Journal of Consulting and Clinical Psychology 71 (2003) 394-398
2. Aouizerate B., Guehl D., Cuny E., Rougier A., Bioulac B., Tignol J., and Burbaud P. Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Progress in Neurobiology 72 (2004) 195-221
3. Baxter L.R. Neuroimaging studies of human anxiety disorders: cutting paths of knowledge through the field of neurotic phenomena. In: Bloom F., and Kupfer D. (Eds). Neuropsychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 1287-1299
4. Baxter Jr. L.R., Schwartz J.M., Bergman K.S., Szuba M.P., Guze B.H., Mazziotta J.C., Alazraki A., Selin C.E., Ferng H.K., Munford P., and Phelps M.E. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Archives of General Psychiatry 49 (1992) 681-689
5. Bollini P., Pampallona S., Tibaldi G., Kupelnick B., and Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 174 (1999) 297-303
6. Bonne O., Louzoun Y., Aharon I., Krausz Y., Karger H., Lerer B., Bocher M., Freedman N., and Chisin R. Cerebral blood flow in depressed patients: a methodological comparison of statistical parametric mapping and region of interest analyses. Psychiatry Research 122 (2003) 49-57
7. Beck A.T., Steer R.A., and Brown G.K. BDI-II Manual. The Psychological Corporation: San Antonio, TX (1996)
8. Brody A.L., Saxena S., Schwartz J.M., Stoessel P.W., Maidment K., Phelps M.E., and Baxter Jr. L.R. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Research: Neuroimaging 84 (1998) 1-6
9. Cavedini P., Riboldi G., D'Annucci A., Belotti P., Cisima M., and Bellodi L. Decision-making heterogeneity in obsessive-compulsive disorder: ventromedial prefrontal cortex function predicts different treatment outcomes. Neuropsychologia 40 (2002) 205-211
10. Chang L.T. A method for attenuation correction in radionuclide computedtomography. IEEE transaction on nuclear. Science 25 (1978) 638-643
11. De Haan E., van Oppen P., van Balkom A.J., Spinhoven P., Hoogduin K.A., and Van Dyck R. Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatrica Scandinavica 96 (1997) 354-361
12. Genovese C.R., Lazar N.A., and Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. NeuroImage 15 (2002) 870-878
13. Goldapple K., Segal Z., Garson C., Lau M., Bieling P., Kennedy S., and Mayberg H. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Archives of General Psychiatry 61 (2004) 34-41
14. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., and Charney D.S. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry 46 (1989) 1006-1011
15. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., and Charney D.S. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Archives of General Psychiatry 46 (1989) 1012-1016
16. Hendler T., Goshen E., Tzila Zwas S., Sasson Y., Gal G., and Zohar J. Brain reactivity to specific symptom provocation indicates prospective therapeutic outcome in OCD. Psychiatry Research: Neuroimaging 124 (2003) 87-103
17. Iikura Y. Treatment Guide for Obsessive-Compulsive Disorder. Nihei-Sha (1999), Osaka
18. Jenike M.A. Drug treatment of obsessive compulsive disorders. In: Jenike M.A., Baer L., and Minichiello W.E. (Eds). Obsessive-Compulsive Disorder: Practical Management (1998), Mosby, New York 469-554
19. Kampman M., Keijsers G.P., Hoogduin C.A., and Verbraak M.J. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatrica Scandinavica 106 (2002) 314-319
20. Kang D.H., Kwon J.S., Kim J.J., Youn T., Park H.J., Kim M.S., Lee D.S., and Lee M.C. Brain glucose metabolic changes associated with neuropsychological improvements after 4 months of treatment in patients with obsessive-compulsive disorder. Acta Psychiatrica Scandinavica 107 (2003) 291-297
21. Lucey J.V., Costa D.C., Blanes T., Busatto G.F., Pilowsky L.S., Takei N., Marks I.M., Ell P.J., and Kerwin R.W. Regional cerebral blood flow in obsessive-compulsive disordered patients at rest. Differential correlates with obsessive-compulsive and anxious-avoidant dimensions. British Journal of Psychiatry 167 (1995) 629-634
22. Mataix-Cols D., Rauch S.L., Manzo P.A., Jenike M.A., and Baer L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry 156 (1999) 1409-1416
23. Mataix-Cols D., Wooderson S., Lawrence N., Brammer M.J., Speckens A., and Phillips M.L. Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Archives of General Psychiatry 61 (2004) 564-576
24. Matsuda H., Ohnishi T., Asada T., Li Z.J., Kanetaka H., Imabayashi E., Tanaka F., and Nakano S. Correction for partial-volume effects on brain perfusion SPECT in healthy men. Journal of Nuclear Medicine 44 (2003) 1243-1252
25. Matsuda H., Mizumura S., Soma T., and Takemura N. Conversion of brain SPECT images between different collimators and reconstruction processes for analysis using statistical parametric mapping. Nuclear Medicine Communications 25 (2004) 67-74
26. Milad M.R., Quinn B.T., Pitman R.K., Orr S.P., Fischl B., and Rauch S.L. Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory. Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 10706-10711
27. Milad M.R., and Rauch S.L. The orbitofrontal cortex and anxiety disorders. In: Zald D.H., and Rauch S.L. (Eds). The Orbitofrontal Cortex (2006), Oxford University Press, New York 523-543
28. Nakatani E., Nakgawa A., Ohara Y., Goto S., Uozumi N., Iwakiri M., Yamamoto Y., Motomura K., Iikura Y., and Yamagami T. Effects of behavior therapy on regional cerebral blood flow in obsessive-compulsive disorder. Psychiatry Research: Neuroimaging 124 (2003) 113-120
29. Nakatani E., Nakagawa A., Nakao T., Yoshizato C., Nabeyama M., Kudo A., Isomura K., Kato N., Yoshioka K., and Kawamoto M. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder-effectiveness of behavior therapy and fluvoxamine. Psychotherapy and Psychosomatics 74 (2005) 269-276
30. Nakao T., Nakagawa A., Yoshiura T., Nakatani E., Nabeyama M., Yoshizato C., Kudoh A., Tada K., Yoshioka K., and Kawamoto M. A functional MRI comparison of patients with obsessive-compulsive disorder and normal controls during a Chinese character Stroop task. Psychiatry Research: Neuroimaging 139 (2005) 101-114
31. Nakao T., Nakagawa A., Yoshiura T., Nakatani E., Nabeyama M., Yoshizato C., Kudoh A., Tada K., Yoshioka K., Kawamoto M., Togao O., and Kanba S. Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biological Psychiatry 57 (2005) 901-910
32. Ninan P.T., Koran L.M., Kiev A., Davidson J.R., Rasmussen S.A., Zajecka J.M., Robinson D.G., Crits-Christoph P., Mandel F.S., and Austin C. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. Journal of Clinical Psychiatry 67 (2006) 15-22
33. Ohnishi T. SPM. In: Matsuda H., and Asada T. (Eds). Imaging Diagnosis for Dementia (2004), Nagai Shoten, Osaka 73-89
34. Pallanti S., Hollander E., and Goodman W.K. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. Journal of clinical Psychiatry 65 Suppl 14 (2004) 6-10
35. Phelps E.A., Delgado M.R., Nearing K.I., and LeDoux J.E. Extinction learning in humans: role of the amygdala and vmPFC. Neuron 43 (2004) 897-905
36. Rauch S.L., Shin L.M., Dougherty D.D., Alpert N.M., Fischman A.J., and Jenike M.A. Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 27 (2002) 782-791
37. Remijnse P.L., Nielen M.M., van Balkom A.J., Cath D.C., van Oppen P., Uylings H.B., and Veltman D.J. Reduced orbitofrontal-striatal activity on a reversal learning task in obsessive-compulsive disorder. Archives of General Psychiatry 63 (2006) 1225-1236
38. Saxena S., Brody A.L., Maidment K.M., Dunkin J.J., Colgan M., Alborzian S., Phelps M.E., and Baxter Jr. L.R. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21 (1999) 683-693
39. Saxena S., Brody A.L., Ho M.L., Alborzian S., Maidment K.M., Zohrabi N., Ho M.K., Huang S.C., Wu H.M., and Baxter Jr. L.R. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Archives of General Psychiatry 59 (2002) 250-261
40. Saxena S., Brody A.L., Ho M.L., Zohrabi N., Maidment K.M., and Baxter Jr. L.R. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. American Journal of Psychiatry 160 (2003) 522-532
41. Saxena, S., Gorbis, E., O'Neill, J., Baker, S.K., Mandelkern, M.A., Maidment, K.M., Chang, S., Salamon, N., Brody, A.L., Schwartz, J.M., London, E.D., 2009. Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Molecular Psychiatry 14, 197-205.
42. Schwartz J.M., Stoessel P.W., Baxter Jr. L.R., Martin K.M., and Phelps M.E. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Archives of General Psychiatry 53 (1996) 109-113
43. Schwartz J.M. Neuroanatomical aspects of cognitive-behavioural therapy response in obsessive-compulsive disorder. An evolving perspective on brain and behaviour. British Journal of Psychiatry (Suppl) (1998) 38-44
44. Spielberger C.D., Gorsuch R., and Lushene R. Manual for the State-Trait Anxiety Inventory. Consulting Psychologist Press, Palo Alto, CA (1970)
45. Takeuchi Y., Tohyama J., Katano H., Mase M., Kanai H., and Yamada K. Identification of motor activation brain perfusion SPECT with brain easy analysis tools. Nagoya Medical Journal 47 (2005) 57-66
46. Tolin D.F., Maltby N., Diefenbach G.J., Hannan S.E., and Worhunsky P. Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial. Journal of Clinical Psychiatry 65 (2004) 922-931
47. Tolin D.F., Abramowitz J.S., and Diefenbach G.J. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown Obsessive Compulsive Scale. Journal of Clinical Psychiatry 66 (2005) 1549-1557
48. Whiteside S.P., Port J.D., and Abramowitz J.S. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Research: Neuroimaging 132 (2004) 69-79